HOME >> MEDICINE >> NEWS
Omega-3 offers hope for new anti-breast cancer drugs

Omega-3, the fatty acid found in oily fish, could be combined with a commonly used anesthetic to develop drugs to treat breast cancer, according to research published today in the journal Breast Cancer Research. Compounds of Omega-3 fatty acids and propofol reduce the ability of breast cancer cells to develop into malignant tumours, inhibiting cancer cell migration by 50% and significantly reducing their metastatic activity. These new compounds could be developed into a new family of anti-cancer drugs.

Dr Rafat Siddiqui, from the Methodist Research Institute and Indiana University in Indianapolis, and his colleagues studied the effect of two Omega-3 fatty acids, docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), combined with propofol on a breast cancer cell line in vitro. Omega-3 fatty acids such as DHA and EPA have a minimal effect on cancer cells when applied alone. Propofol is a potent anti-oxidant known to inhibit cancer cell migration by only 5-10%.

The results of the study show that propofol and DHA or EPA have a much more significant effect on cancer cells when used in combination, as conjugates, than when used alone. The conjugates inhibit cancer cell adhesion by 15% and 30% respectively, reduce cell migration by 50% and increase apoptosis by 40%.

"These results suggest that the novel propofol-DHA and propofol-EPA conjugates reported here may be useful for the treatment of breast cancer" conclude Siddiqui and colleagues.

Malignant cancer cells are highly invasive cells that have lost the ability to sense cues from their environment. As a result, they start dividing abnormally, migrate and accumulate into malignant tumours, in a process called metastasis, which is potentially life-threatening. The aim of anti-cancer drugs is therefore to prevent the cells from dividing abnormally and from spreading, to kill the cells, or to cause the cells to kill themselves.

Fatty acids are often attached to drugs, because
'"/>

Contact: Juliette Savin
juliette@biomedcentral.com
44-207-631-9931
BioMed Central
7-Jun-2005


Page: 1 2

Related medicine news :

1. Omega-3 fatty acids may slow down early Alzheimers in some cases
2. Omega-3 fatty acids may slow cognitive decline in some patients with very mild Alzheimers disease
3. The nude mouse tale: Omega-3 fats save the life of a terminal cancer patient
4. Hormone therapy offers new hope for ovarian cancer patients
5. TB test offers patients quicker and easier diagnosis
6. Panel offers guidelines on skin reactions to new class of cancer drugs
7. Supersize me mice research offers grim warning for Americas fast food consumers
8. New treatment offers relief from chronic back pain
9. Commonly used drug offers promise for premature babies
10. Stenting of abdominal arteries offers welcome relief for intestinal angina
11. Study offers clues to Broken Heart Syndrome

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/24/2017)... ... 24, 2017 , ... In “Sky and I”, a young boy was walking home and feeling down about himself. ... him otherwise. The new friend says he can do whatever he wants to do if ... enough just the way he is. God created him with special talents and gifts. We ...
(Date:9/24/2017)... (PRWEB) , ... September 24, 2017 , ... “The Gospel Truth Of The Bible: The ... “The Gospel Truth Of The Bible: The Other Sheep” is the creation of published author, ... born in the West Indies. He has been a member of the Seventh-day Adventist ...
(Date:9/23/2017)... ... September 23, 2017 , ... Silicon Valley Hair Institute, the leading ... new blog post focused on the ARTAS® hair transplant system and the younger demographic. ... the latest, most technologically sophisticated methods of hair restoration. , “It can be emotionally ...
(Date:9/22/2017)... ... ... MEDIA OPPORTUNITY: , Save Our Hospital - Albert Lea will host media ... against Mayo Clinic. Specifically, media can talk to steering committee members and patients regarding ... the Albert Lea hospital. , The rally aims to protect the most vulnerable and ...
(Date:9/22/2017)... PA (PRWEB) , ... September 22, 2017 , ... ... soon as possible, and they often saves lives. However, if one isn’t accessible ... to widen the availability of defibrillation, I came up with this idea," said ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... -- NeuroRx, a clinical stage biopharma company developing the first ... been granted Fast Track status by the US Food and ... followed by NRX-101 (D-cycloserine + lurasidone). The company will shortly ... therapy targeting patients who are admitted to Emergency Departments with ... ...
(Date:9/5/2017)... another milestone in their continued growth and success of the company.  Xyntek has ... engagements regionally.  ... at 318 West Adams Street, Suite 1528, Chicago, IL ... Xyntek's recently opened Midwest office will support the ... In addition to Xyntek,s headquarters ...
(Date:9/5/2017)... 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... pharmaceutical company focused on the development of oral drug ... its meeting with the U.S. Food and Drug Administration ... At the meeting, ... for submission of ORMD-0801, would be a Biologics License ...
Breaking Medicine Technology:
Cached News: